Support for sorghum and millet research

The International Sorghum and Millet Collaborative Research Support Program (INTSORMIL) based at the University of Nebraska-Lincoln “works to improve nutrition and natural resource management and to increase income in developing countries, while developing new technologies to improve sorghum and pearl millet production and its use worldwide.” CropBiotech Update recently announced that the US Agency for International Development (USAID) has given INTSORMIL a grant of US$9 M to continue enabling “plant breeders from U.S. land-grant universities to work with researchers in host countries through education, mentoring and collaborative research.” Sounds very worthy, but I must admit I hadn’t heard of this outfit before.

Market assisted selection

There’s a discussion of marker assisted selection (MAS) in, of all places, the Guardian. The writer, Jeremy Rifkin, tries to sell MAS as a consumer-friendly alternative to GM, but judging by some of the comments that is not going to be a universally successful strategy.

Stronger, straighter bananas

Is biofortification still the next big thing, or is it yesterday’s news already? Anyway, here’s an article on an Australia-Uganda collaboration on bananas funded by the Bill and Melinda Gates Foundation. But Pohnpei nutritionist Dr Lois Englberger has reminded me that foods do not contain vitamin A, as implied in the article. They contain vitamin A precursors, provitamin A carotenoids, mainly beta-carotene, which the body uses to synthesize vitamin A.

Underutilized biotechnologies?

The International Centre for Underutilized Crops (ICUC) has a position paper on the use of biotechnology to promote and develop neglected and underutilized species. You can download it here. The study concludes that some biotechnologies, eg tissue culture and microproagation, have proved effective in enhancing the use of neglected species, but that others, eg DNA fingerprinting for genetic diversity studies, have resulted in only limited practical benefits. The risks associated with applying biotechnologies include centralization, intellectual property protection and the formation of genetic bottlenecks.